

Supplementary Table 1. Demographic and clinical characteristics of SLE patients and healthy controls.

	SLE (n=71)	HC (n=25)
Age (years)	32.1 ± 13.7	26.4 ± 3.4
Female/Male	64/7	23/2
Duration of diagnosis(years)	4.8 ± 5.4	/
SLEDAI score	8.8 ± 4.7	/
Anti-dsDNA , IU/mL ^a	284.4 ± 322.5	/
Albumin, g/L	28.8 ± 8.9	/
Globulin, g/L	26.9 ± 7.4	/
IgG, g/L	13.5 ± 8.2	/
Serum C3 , g/L	0.52 ± 0.25	/
Serum C4, g/L	0.11 ± 0.08	/
Serum Creatinine, μmol/L	134.2 ± 168.7	/
WBC, 10 ⁹ /L	7.4 ± 4.2	/
Lymphocyte, 10 ⁹ /L	1.1 ± 0.8	/
Platelet, 10 ⁹ /L	203.7 ± 102.7	/
Urinary protein, g/24h	2.7 ± 3.4	/
Microscopic hematuria, RBC/HPF	13.9 ± 12.9	/
Medication (%)	100%	/
Prednisone or methylprednisolone	98.4%	/
Hydroxychloroquine	81.3%	/
Cyclophosphamide	26%	/
Mycophenolate mofetil	15.6%	/
Cyclosporin A	18.7%	/

Note: All data are expressed as mean ± SD. SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Index; HC, health controls; WBC, White blood cells.

^a Normal reference range of anti-dsDNA is **0-12** IU/ml.